For example, (1) Yang and colleagues have shown that liraglutide reversed the impairment of AKT and GSK-3β phosphorylation and also ameliorated tau hyperphosphorylation in type 2 DM rats [53]; and (2) McLean and colleagues also demonstrated that liraglutide reduced Aβ plaque deposition with improving cognitive function in early-stage APP/PS1 mice with AD [54] and in late-stage AD mice [55]. This evidence concerns the gene GSK3B and Alzheimer disease.